Ann: SCENESSE in Adolescent EPP Study, page-6

Yeah that comment won't do his voting support much good, when I look at my screen I see the SP down 20% YTD and nearly that much for 12 months and for the olympic cycle that Wolgen talks so fondly of we are down a lot more from pre FDA approval and much more for buyers who bought in on the positive FDA decision. For such a secretive, controlling company it is really amazing they allow the SP to form the narrative and dictate almost the entire conversation regarding management, decisions, competence, remuneration, incentives that don't align with shareholder interests and so on. So simple just to start a share buyback and return some shareholder funds to shareholders in this fashion while benefitting the company forever by reducing shares on issue and increasing EPS(forever), I don't see the cash being used wisely or at all so the board should address this and put shareholders front and centre for a change. If Disc can get a market cap over twice the CUV market cap then it's not that hard, they are years away from entering the EPP market with their lead drug if ever and are certainly not pumping out an EPS of 0.62 like CUV is.

All IMO DYOR